The global antacid medicine market showed diverse trends in 2023, with South Korea leading sales at $92.0 million PPP, reflecting a positive growth rate of 2.08% from the previous year. Notable growth was observed in Austria (10.07%) and Latvia (10.76%). However, Croatia and Denmark experienced slight declines, at -0.53% and -0.55% respectively. Some countries like Slovakia and Portugal showed sharper declines in their sales at -4.07% and -1.0% respectively.
Looking ahead in 2024, global trends may reflect increased emphasis on dietary health and an aging population. Emerging markets might represent significant growth opportunities, while established markets could see stabilization influenced by healthcare advancements and lifestyle changes.
Top countries in Antacid Medicine Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 South Korea | 92 | 2023 | -0.65% | +2.08% | View data |
| 2 | 2 Croatia | 22.2 | 2023 | 0% | -0.53% | View data |
| 3 | 3 Denmark | 10.7 | 2023 | +0.94% | -0.55% | View data |
| 4 | 4 Greece | 10.4 | 2023 | -0.95% | +3.87% | View data |
| 5 | 5 Portugal | 9.7 | 2023 | -1.02% | -1% | View data |
| 6 | 6 Austria | 2.1 | 2023 | +10.53% | +10.07% | View data |
| 7 | 7 Latvia | 1.5 | 2023 | +7.14% | +10.76% | View data |
| 8 | 8 Slovakia | 1.3 | 2023 | 0% | -4.07% | View data |
| 9 | 9 Estonia | 1.2 | 2023 | 0% | +8.45% | View data |
| 10 | 10 Luxembourg | 0.4 | 2023 | 0% | 0% | View data |
